GlassScriptPhysician profile
Todd Michael Verhoef
NPI 1801885033
$1,081.40
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $362 · 2021: $145 · 2022: $49.40.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $502.93 | 2019-2020 | |
| Abbvie INC. | $194.56 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $119.00 | 2019 | |
| Sunovion Pharmaceuticals INC. | $92.43 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $35.36 | 2019 | |
| Vanda Pharmaceuticals INC. | $28.49 | 2020 | |
| Lundbeck LLC | $28.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.88 | 2019 | |
| Neos Therapeutics, LP | $17.31 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.27 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.49 | 2020 | |
| Shire North American Group INC | $12.19 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Verhoef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.